

IN THE SPECIFICATION:

Replace the paragraph starting at column 3, line 58 through column 4, line 2 with the following paragraph:

The present invention is also directed to a chimeric antibody specific for a human colon carcinoma-associated protein antigen wherein the antigen is not detectable on normal human tissues or on human carcinoma cells other than colon carcinoma cells. Mouse hybridoma PCA 31.1 has been deposited at ATCC and assigned [ATCC HB-12314] PTA-2497. Mouse hybridoma PCA 33.28 has been deposited at ATCC and assigned ATCC HB 12315. Cells transfected with chimeric 31.1 have been deposited at ATCC and assigned ATCC CRL-12316. The above deposits were made at American Type Culture Collection, at [12301 Parklawn Drive, Rockville, Md 20862 USA on March 13, 1997] 10801 University Boulevard, Manassas, VA 20110-2209.

IN THE CLAIMS:

1. (amended) A monoclonal antibody specific for a purified human colon carcinoma-associated protein antigen, wherein said antigen has the following characteristics:

- (a) [said antigen is purified to the extent that the membrane fractions are free of HL-A antigen and are substantially free from non-immunogenic glycoprotein fractions] said antigen is purified to the extent that the membrane fractions are free of HL-A antigen and are substantially free from non-immunogenic glycoprotein fractions;
- (b) said antigen is not detectable on normal colon cancer free human tissues;

- (c) said antigen is not detectable on human carcinoma cells other than colon carcinoma cells;
- (d) said antigen is specifically immunogenic in humans; and
- (e) said antigen induces an immune response in humans having colon carcinoma which is expressed as cell mediated immunity.

30. (amended) A compartmentalized kit for detection of a human colon carcinoma-associated antigen, wherein the antigen has the following characteristics:

- (a) [said antigen is purified to the extent that the membrane fractions are free of HL-A antigen and are substantially free from non-immunogenic glycoprotein fractions] said antigen is purified to the extent that the membrane fractions are free of HL-A antigen and are substantially free from non-immunogenic glycoprotein fractions;
- (b) said antigen is not detectable on normal colon cancer free human tissues;
- (c) said antigen is not detectable on human carcinoma cells other than colon carcinoma cells;
- (d) said antigen is specifically immunogenic in humans; and
- (e) said antigen induces an immune response in humans having colon carcinoma which is expressed as cell mediated immunity,

said kit comprising a first container adapted to contain an antibody to said antigen or an active component thereof, said second antibody being labeled with a reporter molecule capable of giving a detectable signal.

33. (amended) A kit according to claim [30] 32 wherein the kit further comprises a third container adapted to contain a substrate for the enzyme.

34. (amended) A compartmentalized kit for detection of a human colon carcinoma-associated antigen, wherein the antigen has the following characteristics:

- (a) [said antigen is purified to the extent that the membrane fractions are free of HL-A antigen and are substantially free from non-immunogenic glycoprotein fractions] said antigen is purified to the extent that the membrane fractions are free of HL-A antigen and are substantially free from non-immunogenic glycoprotein fractions;
- (b) said antigen is not detectable on normal colon cancer free human tissues;
- (c) said antigen is not detectable on human carcinoma cells other than colon carcinoma cells;
- (d) said antigen is specifically immunogenic in humans; and
- (e) said antigen induces an immune response in humans having colon carcinoma which is expressed as cell mediated immunity,

said kit comprising a first container adapted to contain monoclonal antibody 31.1 (ATCC HB-12314) to said antigen and a second container adapted to contain a second antibody to said antigen or an active component thereof, said second antibody being labeled with a reporter molecule capable of giving a detectable signal.

36. (amended) A kit according to claim [32] 34 wherein the reporter molecule is an enzyme.

37. (amended) A kit according to claim [33] 36 wherein the kit further comprises a third container adapted to contain a substrate for the enzyme.

38.(amended) A compartmentalized kit for detection of a human colon carcinoma-associated antigen, wherein the antigen has the following characteristics:

- (a) [said antigen is purified to the extent that the membrane fractions are free of HL-A antigen and are substantially free from non-immunogenic glycoprotein fractions] said antigen is purified to the extent that the membrane fractions are free of HL-A antigen and are substantially free from non-immunogenic glycoprotein fractions;
- (b) said antigen is not detectable on normal colon cancer free human tissues;
- (c) said antigen is not detectable on human carcinoma cells other than colon carcinoma cells;
- (d) said antigen is specifically immunogenic in humans; and
- (e) said antigen induces an immune response in humans having colon carcinoma which is expressed as cell mediated immunity,

said kit comprising a first container adapted to contain monoclonal antibody 33.28 (ATCC HB-12315) to said antigen and a second container adapted to contain a second antibody to said antigen or an active component thereof, said second antibody being labeled with a reporter molecule capable of giving a detectable signal.